TRAXENS
19.9.2018 16:02:11 CEST | Business Wire | Press release
TRAXENS today announced that ERCI Eurail Clusters has named TRAXENS DIGITAL FREIGHT TRAIN, Europe's first Freight Train to use an innovative IoT-based system allowing digitalization of operations, the winner of their « Coup de Cœur » Innovation Award. The prize has been given to the company at the InnoTrans 2018 tradeshow in Berlin.
Initially launched with Fret SNCF, the TRAXENS DIGITAL FREIGHT TRAIN solution is based on smart devices capable of communicating with each other using wireless digital network. TRAXENS solution goes beyond smart wagons to connect the entire train offering new high-value-added services.
Inherited from the Shipping Industry, TRAXENS DIGITAL FREIGHT TRAIN has been designed to work worldwide and manage any type of asset (e.g., Dry or Reefer container, wagon, trailer) which means that rail freight can be connected to the rest of the supplier chain anywhere, to explore and leverage door-to-door multimodal applications.
« This industry recognition is a major milestone for us. We have achieved to design and implement with our partner SNCF Logistics such a solution in a two-year timeframe, which has never been experienced in the industry. We are looking forward to extending the solution worldwide, said Florence Delalande, Rail Business Unit Director at TRAXENS.
Dirk-Ulrich Krüger, Spokesperson of the European Railway Clusters Initiative, comments: « We are thrilled to recognize next-generation innovation in the railway industry, and that’s why TRAXENS has earned this award from ERCI Eurail Clusters. Some of the best solutions, come from these kinds of forward-thinking players who think outside of the box. »
The DIGITAL FREIGHT TRAIN innovation enables the stakeholders of the railway ecosystem to share benefits and costs:
Railway undertakings optimise their wagon fleet and streamline operations.
Shippers geolocate their shipments in real-time anywhere around the world and receive alerts when their shipment arrives at key locations
Wagon keepers can use preventive and predictive maintenance based on hard facts (accurate mileage tracking, information on abnormal shocks, brake and axle monitoring).
Customized services are possible: remote control, door opening, temperature and humidity monitoring.
About ERCI Innovation Awards
The ERCI Innovation Awards recognize companies from ERCI partner clusters that have successfully introduced innovative products or solutions to the market. The prize is initiated by the European Railway Clusters Initiative (ERCI).
The categories of the ERCI Innovation Awards are:
- “Best Large Enterprise”
- “Best SME”
- “Coup de Cœur” special jury prize
The term of the award is annually. Hosting of the award ceremony rotates among the ERCI members. The 2018 awarding ceremony was hosted by the Cluster Transport, Mobility and Logistics Berlin-Brandenburg at InnoTrans 2018 on Wednesday, 19 September 2018.
The awarding ceremony, which took place at the Berlin-Brandenburg joint booth in the CityCube, hall B, on Wednesday, 19 September 2018, was organised by the ERCI partner Cluster Transport, Mobility and Logistics in Berlin and Brandenburg with support from Berlin Partner of Business and Technology. The ERCI Innovation Awards Ceremony took place for the fourth time in 2018:
About ERCI
The European Railway Clusters Initiative was founded in 2010 with the signature of the cooperation treaty on InnoTrans 2010. Member clusters of ERCI are:
- I-Trans competitiveness cluster (Famars, France)
- BTS Rail Saxony (Dresden, Germany)
- Cluster Mobilität, Verkehr und Logistik Berlin-Brandenburg, c/o Berlin Partner for Business and Technology (Berlin, Germany)
- CNA Cluster Bahntechnik Bayern (Nuremberg, Germany)
- DITECFER (Pistoia, Italy)
- Inno-Pro (Karup, Denmark)
- Järnvägsklustret (Västeras, Sweden)
- Logistics in Wallonia (Grace-Hollogne, Belgium)
- The Rail Alliance (Birmingham, UK)
- Railgrup (Barcelona, Spain)
- Southern Railway Cluster (Katowice, Poland)
The 11 partner clusters represent more than 1,000 companies from railway industry from all over Europe. ERCI aims aims to promote innovation and the development of new business opportunities as a means of sustainably bolstering competitiveness within the European railway industry. ERCI fosters collaboration between industry and research, initiates innovation projects and organises B2B meetings and workshops. This also includes the promotion of good visibility and networking at EU level.
Projects with participation of ERCI partner clusters include
-
PERES (Promoting European Rail Excellence outSide EU), an ESCP 4i
partnership under the roof of the European Cluster Collaboration
Platform (ESCP).
More information: http://www.peresinfo.com/ - RECORD (Regions in Europe Coordinate and Optimize innovation and competitiveness policy instruments towards improving the sustainability of transport – study case of SMEs in the railway sector). More information: https://www.interregeurope.eu/record/
About TRAXENS :
TRAXENS delivers the world's most exhaustive, precise and timely information about containers in transit anywhere in the world using breakthrough technology and Big Data techniques. This information provides all stakeholders in multi-modal transport the opportunity to improve costs, optimize investment, and offer premium services.
For more information: www.traxens.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20180919005029/en/
Contact:
Press Contact: TRAXENS Geraldine Sauniere, Tel: +33-6-95-91-58-99 Director of Communications g.sauniere@traxens.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom